NEW DELHI: The Union government has told the Supreme Court that hospital overcharging for medicines and everyday medical consumables is "malpractice", a striking admission in an ongoing public interest case that seeks caps on the prices of all medicines and medical supplies. The statement came in an affidavit reported on October 23, 2026, and puts hospital billing practices directly under judicial scrutiny.
The affidavit was filed in a case that asks the court to cap prices of medicines and medical consumables sold inside hospitals. The chemicals and fertilisers ministry told the court that patients have very little bargaining power against hospitals, a point that sits at the centre of the debate over hospital overcharging in private healthcare.
The bench of Justices Vikram Nath and Sandeep Mehta has already taken a strong view of drug pricing. During earlier hearings it described inflated drug prices as "broad daylight dacoity" and suggested capping maximum retail prices at 16 per cent above the price charged to retailers.
Judicial scrutiny had earlier turned up stark figures. Cancer formulations sold to patients carried maximum retail prices up to ten times the price charged to retailers. In one example placed before the court, a cancer drug bought by a retailer for Rs 2,700 carried a maximum retail price of Rs 27,000, a spread the judges treated as a clear instance of hospital overcharging.
Why hospital overcharging escapes ordinary market checks
Patients arriving in emergency rooms cannot compare prices, audit medicine labels or negotiate terms before consenting to treatment. Many private hospitals also require drugs and supplies to be bought from internal pharmacies, leaving families with little option but to pay the bill as printed. The ministry said this structural imbalance is why hospital overcharging persists even where cheaper alternatives exist.
Oncology patients feel the pressure hardest. Long treatment cycles of chemotherapy, supportive drugs and repeated monitoring mean each inflated bill compounds over months. For families paying from savings rather than insurance, the cumulative cost can push a household toward debt.
The hospital overcharging numbers before the court
Retail mark-ups on anti-cancer drugs run from 170 per cent to more than 700 per cent, according to findings placed before the court. For everyday consumables such as syringes, surgical dressings, intravenous tubing, catheters and sterile gloves, mark-ups span 100 per cent to upwards of 1,000 per cent above procurement rates.
Small items add up. During an intensive care stay or a surgery, consumables billed at the ceiling price can run into tens of thousands of rupees. The affidavit said that when supplies are billed at maximum retail price instead of negotiated institutional rates, out-of-pocket patients absorb the full difference.
Justice Mehta observed that hospitals charge Rs 2,000 for a medicine meant to sell at Rs 200 and then claim reimbursement under Ayushman Bharat, so taxpayers end up footing the inflated bill. That observation ties hospital overcharging directly to public money.
What the government and hospitals say about hospital overcharging
India already has price-control machinery. The National Pharmaceutical Pricing Authority sets ceiling prices for scheduled formulations under the Drugs (Prices Control) Order, and court records show 935 scheduled formulations with ceiling prices, with retail prices monitored for 3,881 newer drugs. Even so, many non-scheduled drugs and consumables sit outside direct caps.
The Clinical Establishments Act, 2010 asks hospitals to display rates publicly, but health is a state subject and enforcement rests with individual states. In March 2025 the Supreme Court asked states to frame rules stopping hospitals from forcing patients to buy supplies from internal pharmacies.
Hospitals argue the spreads cover real overheads, including bio-waste disposal, cold-chain refrigeration, infection control, sterile handling and staff salaries. Industry voices also warn that capping product mark-ups without touching room or procedure charges could push providers to raise other fees or cut investment in clinical infrastructure.
The government told the court that uniform caps on every consumable would be hard to run because of gaps in procurement data, and that it needs invoices matched against patient bills before it can fix standard rates. But its central admission stands: hospital overcharging is malpractice, not ordinary retail.
The court has asked the Centre to keep exploring regulatory remedies, including the suggested cap of 16 per cent above the price charged to retailers. The case continues.